^Dogra S, Shah S, Gitzel L, Pusukur B, Sood A, Vyas AV, Gupta R (July 2023). "Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension". Current Problems in Cardiology. 48 (11): 101918.
doi:
10.1016/j.cpcardiol.2023.101918.
PMID37399857.
S2CID259320969.
^Awosika A, Cho Y, Bose U, Omole AE, Adabanya U (October 2023). "Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension". Expert Opinion on Investigational Drugs: 1–11.
doi:
10.1080/13543784.2023.2276755.
PMID37883217.
S2CID264517675.
^Dogra S, Shah S, Gitzel L, Pusukur B, Sood A, Vyas AV, Gupta R (July 2023). "Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension". Current Problems in Cardiology. 48 (11): 101918.
doi:
10.1016/j.cpcardiol.2023.101918.
PMID37399857.
S2CID259320969.
^Awosika A, Cho Y, Bose U, Omole AE, Adabanya U (October 2023). "Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension". Expert Opinion on Investigational Drugs: 1–11.
doi:
10.1080/13543784.2023.2276755.
PMID37883217.
S2CID264517675.